anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to means and methods for conjugating/linking target molecules, such as proteins, to labels and/or carriers. In particular, the present invention provides a complex comprising a metal cation coordinated to (i) a nitrate metal cation ligand and (ii) a metal cation chelating domain, wherein the metal cation chelating domain comprises a chelating ligand and a label and/or a carrier. The complexes can be used to attach labels and/or carriers to target molecules, preferably proteins. Attachment of the label or support by the complexes of the invention involves displacement of the metal cation ligands by the coordinating groups of the target molecule, thereby forming a product complex having the target molecule as the primary ligand in the coordination sphere of the metal cation. Thus, the invention also provides uses and methods comprising attaching labels and/or vectors to target molecules. Also provided are products obtained by the marking and/or vector linking methods of the invention and uses thereof. The invention further relates to methods of producing the complexes of the invention and kits comprising components for producing the complexes of the invention.
The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. Both groups are offered equal general advice of physical activity.
This study is a prospective, open-label, non-interventional study. The objective of this study is to investigate the utility of fentanyl matrix after 8 week treatment of fentanyl matrix for the treatment of pain due to osteoarthritis (OA) of knee or hip, which was not adequately controlled by non-opioid analgesic (e.g. NSAIDs or COX-II selective inhibitors) or weak opioids \[tramadol HCl with acetaminophen, tramadol or codeine (or combination with acetaminophen/ibuprofen)\] in clinical practice according to the investigator's discretion. This study will investigate the usefulness of fentanyl matrix based on improvement in pain and function after Fentanyl matrix administration in patients who complained of pain caused by osteoarthritis and indicated for Fentanyl matrix administration in clinical practice at the investigator's discretion. This study will also measure the patients' functional improvement through Korean Version of WOMAC. Observational study - No investigational drug administered
PRKAG2 cardiomyopathy is a rare genetic disorder that manifests early in life with an autosomal dominant inheritance pattern. It harbors left ventricular hypertrophy (LVH), ventricular pre-excitation and progressively worsening conduction system defects. Its estimated prevalence among patients with LVH ranges from 0.23 to about 1%, but it is likely an underdiagnosed condition. We report the association of the PRKAG2 missense variant c.1006G>A p. (Val336Ile) with LVH, conduction abnormalities (short PR interval and incomplete right bundle branch bock) and early-onset arterial hypertension (AH) in a 44-year-old Caucasian patient. While cardiac magnetic resonance (CMR) showed a mild hypertrophic phenotype with maximal wall thickness of 17 mm in absence of tissue alterations, the electric phenotype was relevant including brady-tachy syndrome and recurrent syncope. The same variant has been detected in the patient's sister and daughter, with LVH + early-onset AH and electrocardiographic (ECG) alterations + lipothymic episodes, respectively. Paying close attention to the coexistence of LVH and ECG alterations in the proband has been helpful in directing genetic tests to exclude primary cardiomyopathy. Hence, identifying the genetic basis in the patient allowed for familial screening as well as a proper follow-up and therapeutic management of the affected members. A review of the PRKAG2 cardiomyopathy literature is provided alongside the case report.
Hemodialysis patients aged 18 years and older who have arteriovenous fistula and have been on hemodialysis for more than three months will be included in the control group. No intervention will be made to the control group. Patients in this group will receive routine check-ups and hemodialysis treatments.
Dementia, regardless of its cause, has been recognized to be one of the most important and common problems among the elderly worldwide. The prevalence of dementia has been increasing gradually throughout the world. It is associated with medical and psychological consequences, especially in the advanced stage of the condition. Medications for dementia, specifically, acetylcholine esterase inhibitors, have proven efficacy but variable individual response. They are very expensive and stress families and insurance payers. Dementia and its neuropsychiatric co-morbidities effects not only individual patients, but also family members and care givers as it stresses interpersonal relationships, increases the need for personal care, nursing home placement, and the use of neuropsychiatric medications. Any new approach to improve cognitive function, behavior, mood and sleep quality among demented individuals therefore could have far reaching benefits for patients, care givers, financially responsive parties, and the country as a whole.

There are several studies focusing on the non-pharmacologic approaches to care of the demented. The objectives were to reduce reliance on prescribed medications with these adjunctive therapies. One of the interesting non-drug trials was about music therapy. It was found that music could improve behavioral and social functions among individual demented patients. However, the methodology of each music study varied considerably. To our knowledge, there has been no music study in dementia performed in Thailand using our unique Thai traditional music. We therefore aim to study this non-pharmacologic approach in Thai demented individuals using Thai traditional music. We hypothesized that regular listening to Thai traditional music will improve cognitive function, activities of daily living, mood, behavior and sleep quality in Thai demented patients.
Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
PROBLEM TO BE SOLVED: To obtain the subject composition which has tyrosinase inhibitory activity and is useful in the lightening in color of the skin or the dermatological treatment of pigment stigma by including an acetone-α,α'-dioxalate type compound as an active ingredient. SOLUTION: This composition contains a compound of the formula (R and R' are each a 1-6C alkyl or H) or its physiologically permissible salt in a physiologically permissible medium. As the compound of the formula, diethyl acetone-α,α-dioxalate is particularly favorable. It is desirable that this composition contains the compound of the formula as an active component in the form enclosed in a ribosomal vector. Further, the active component of the formula is preferably contained in a proportion of 0.1-5 wt.% in this composition The medium used in this composition is mainly composed of water and when necessary, an auxiliary used in a cosmetic or a preparation for external use for the skin can be added. By this process, the lightening in color of the skin or the treatment and prevention of pigment stigma is expectable.
Method of Levels Therapy Intervention - Clients will choose how many sessions to attend during the 6 months therapy window. Clients will also choose how often to attend sessions and the duration of each session.
Aberrant expression of forkhead box transcription factor 1 (FOXM1) plays critical roles in a variety of human malignancies and predicts poor prognosis. However, little is known about the crosstalk between FOXM1 and long noncoding RNAs (lncRNAs) in tumorigenesis. The present study identifies a previously uncharacterized lncRNA XLOC_008672 in gastric cancer (GC), which is regulated by FOXM1 and possesses multiple copies of tandem repetitive sequences. LncRNA microarrays are used to screen differentially expressed lncRNAs in FOXM1 knockdown GC cells, and then the highest fold downregulation lncRNA XLOC_008672 is screened out. Sequence analysis reveals that the new lncRNA contains 62 copies of 37-bp tandem repeats. It is transcriptionally activated by FOXM1 and functions as a downstream effector of FOXM1 in GC cells through in vitro and in vivo functional assays. Elevated expression of XLOC_008672 is found in GC tissues and indicates worse prognosis. Mechanistically, XLOC_008672 can bind to small nuclear ribonucleoprotein polypeptide A (SNRPA), thereby enhancing mRNA stability of Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) and, consequently, facilitating GC cell proliferation and migration. Our study discovers a new uncharacterized lncRNA XLOC_008672 involved in GC carcinogenesis and progression. Targeting FOXM1/XLOC_008672/SNRPA/G3BP1 signaling axis might be a promising therapeutic strategy for GC.
PURPOSE: A composition for improving sexual function containing arginine derivative compound is provided to promote expression of iNOS and NO generation in endothelial cells. CONSTITUTION: An arginine derivative having an effect of improving sexual function is denoted by chemical formula 1 or 2. The arginine derivative compound contains an optical isomer and exists in a form of acid or base additive. A composition for improving sexual function contains arginine derivative compound of chemical formula 1 or 2 and its pharmaceutically acceptable salt as active ingredient. The composition is used in the form of drink, beverage, tea bag, capsule, powder, or table food. The composition is also used in the tablet, pill, soft and hard capsule, liquid, suspension, emulsion, syrup, granule or elixirs.
South Africa is home to the world's largest antiretroviral therapy (ART) program, but sustaining high retention along the HIV care continuum has proven challenging in the country and throughout the wider region. Population mobility is frequent in South Africa and mobility likely disrupts retention in HIV care. In the absence of a facility-linked national electronic health data system, clinic switching as unreported transfers also obscures the true magnitude of loss to follow-up, hindering national evaluation efforts. Postpartum women in South Africa are known to be at high risk of dropping out of HIV care after delivery and are frequently mobile, partly due to cultural traditions of returning to one's rural home after giving birth. To address these challenges to retention in care, the investigators will enroll 30 peripartum, HIV-positive women as potential users to assess the acceptability and feasibility of deploying in a real-world setting a novel mHealth application to improve retention in HIV care. The app will operate on users' own smartphones and will serve two primary functions: 1) as a service tool to inform postpartum, HIV-positive women of ART services in their area so that they may access continued HIV care, even while traveling, and 2) as a research tool to prospectively characterize travel and mobility patterns of these women. During this pilot study, women will be passively followed for 90 days following app installation at enrollment. After 90 days, they will be interviewed to determine acceptability and feasibility, and electronic user data will be analyzed. This information will be used to develop an app poised for nationwide adoption. The research team comprises leaders in the study of HIV implementation science, maternal/child health and biomedical informatics, with experience designing effective mobile health (mHealth) interventions in low-resources settings. This pilot study aims to engage potential users to test a smartphone application that both improves linkage to HIV care and provides essential research data to inform future health system strengthening efforts.
Using a randomized, cross-over (balanced incomplete block) experimental design, Forty-eight middle-aged adults who are overweight and have high blood total cholesterol and LDL-C concentrations will be recruited. Participants will consume a HEP - all foods provided - during 5-week controlled feeding periods. The three HEP interventions will be: high RM, low NSS; moderate RM, moderate NSS; and low RM, high NSS. Each participant will complete two of the three controlled feeding periods, separated by four weeks when participants will consume their usual unrestricted diet (washout). The HEP consumed during the controlled feeding periods will be the same except for the amounts of RM (1, 5, or 9, 3-oz servings/wk) and NSS (high, moderate, and low, with amounts adjusted to isocalorically offset changes in RM energy intakes). Poultry, egg, and legume intakes will be the same among the three HEP. The investigators will measure clinically important cardiovascular disease risk factors before (usual unrestricted diet) and during the last week of each HEP intervention. The cardiovascular disease risk factors will include, but are not limited to, comprehensive lipid and lipoprotein profile (changes in low-density lipoprotein cholesterol, LDL-C; primary outcome), lipoprotein fractionation and particle numbers, and blood pressure. The investigators will compare improvements in heart disease risk factors and consumer satisfaction among the three HEP.
The invention discloses a medicated food additive capable of improving intestines and stomach digestion environment. When the medicated food additive is added into soup or porridge to eat, the state of human indigestion can be adjusted, and the digestion environment in human body can be improved. The medicated food additive is prepared by codonopsis pilosula, red dates, alpinia japonica, white hyacinth bean and powdered sugar. A preparation method comprises the following steps: (1) stir-frying the white hyacinth bean, smashing the white hyacinth bean to 120-200 meshes of fine powder for standby application after cooling; (2) adding 3-5 times of water to the codonopsis pilosula and the red dates for heating to extract, respectively extracting two times as each time is 1.5-2 hours, filtering and combining two filter liquor, and concentrating to the relative density of 1.35-1.38 during hot test at 85 DEG C to obtain thick paste for standby application; (3) mixing the thick paste, the white hyacinth bean powder and the powdered sugar, preparing particles according to a conventional method, and packaging after drying. When the medicated food additive is added into soup or porridge to eat, the role of adjusting intestines and stomach indigestion can be played, the digestion environment of human gastrointestinal tract can be improved, and the abdomen bilges unwell feeling can be eliminated. The medicated food additive is reasonable in formula, simple in process and easy to implement.
Hormonal contraceptives should not be used during pregnancy.

Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy.

Combination hormonal contraceptives, such as NuvaRing®, should not be used to induce withdrawal bleeding as a test for pregnancy. NuvaRing® should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any woman who has not adhered to the prescribed regimen for use of NuvaRing® and has missed a menstrual period or who has missed two consecutive periods, pregnancy should be ruled out.
The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
<P>PROBLEM TO BE SOLVED: To provide an oral composition not only increasing the intake of calcium but also promoting the osteogenesis.  <P>SOLUTION: The oral composition for promoting the osteogenesis is characterized as comprising a difructose anhydride as an active ingredient. Calcium, magnesium, phosphorus, isoflavone, vitamin K and vitamin D may further be contained in the composition. The composition provides calcium absorbefacient actions and is further associated with promotion of the osteogenesis and remarkably promotes the osteogenesis. The composition can be used as a medicine or a food and drink for humans or animals.  <P>COPYRIGHT: (C)2004,JPO
Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
* Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3]. 
  * Increased risk of development of lymphoma and other malignancies, particularly of the skin, due to immunosuppression [see Warnings and Precautions (5.3)] . 
  * Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections [see Warnings and Precautions (5.4, 5.5)] . 
  * Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolic acid delayed-release tablets. Patients receiving mycophenolic acid delayed-release tablets should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.2)] .
Light at a therapeutic wavelength is applied to a patient's blood while that blood remains in the body. A port is surgically implanted in the patient. A UV pack or a UV device is connectable to the port. The UV pack has a battery or other power supply and a UV light source. The UV light source is typically LEDs. The UV pack is connected to the port via a tube or catheter. A fiber optic strand or bundle runs through the tube to provide the UV light to the blood. Similarly, the UV device is connected to the port via a tube or catheter. A fiber optic bundle or other light guide directs the light to the blood.
The proposed development study entitled, Tailored Mobile Text Messaging to Reduce Problem Drinking is designed to develop and test a tailored adaptive text messaging/short message service (SMS) intervention for individuals interested in stopping or reducing their alcohol consumption. This intervention includes messages tailored to baseline assessment results (including drinking times) that are adaptive to ongoing drinking patterns and goal achievement via interactive ecological momentary assessment (EMA). Other features include participant initiated help messaging and support network alerts. We will conduct beta research with 40 problem drinkers to assess messaging preferences and acceptability, and then conduct a pilot test with 10 PDs. In Stage 1b, we aim to test this intervention and understand the mechanisms of action of different text messaging interventions with 200 problem drinkers over a 12-week period. We propose to compare four types of messaging: 1) Tailored content and timed messaging adaptive to the participants current state (Stage 1a intervention); 2) Tailored content messaging (not adaptive or timed) sent at 3 pm every day; 3) Untailored consequence based messages sent at 3 pm every day; and 4) Brief feedback and EMA only. Assessments will be completed at baseline, through weekly EMA via SMS and at week 12 via a web-based follow-up assessment. Primary outcomes include drinks per drinking day, days of heavy drinking, and average drinks per week as measured through weekly EMA. Additional outcomes will include drinking related consequences, goal commitment and intervention satisfaction. Outcomes will be used to modify the intervention and to prepare for a larger Stage 1c RCT.
The invention discloses a medicinal and edible traditional Chinese medicine composition with benefiting qi and nourishing blood functions. The composition has a good effect of treating qi and blood deficiency caused in the chemoradiotherapy process. The traditional Chinese medicine composition is prepared from ginseng, donkey-hide gelatin, arillus longan, semen sesami nigrum, orange peel, Chinese yam, red dates, black rice, resistant dextrin and fructo-oligosaccharide. A preparing method includes the steps that the raw materials are dried, mixed, smashed into fine powder, and then smashed in a superfine mode to obtain micro powder. The composition has the effects of strengthening the spleen in transportation, benefiting qi and nourishing blood and is used for adjuvant therapy for patients with spleen deficiency and qi and blood deficiency after chemoradiotherapy. In clinic trial, no adverse effects occur, and the therapeutic effect is remarkable.
RATIONALE AND OBJECTIVES: Percutaneous lung tumor ablations are mostly performed in computed tomography (CT) rooms under local anesthesia with conscious sedation. However, maintaining the breath-hold phase during this can be challenging, affecting image quality and increasing complications. With the advent of hybrid operating rooms (HORs), this procedure can be performed with endotracheal tube (ETGA) intubation under general anesthesia with lung separation, ensuring precise imaging in a single-stage setting. Lung separation provides surgical exposure of one lung while ensuring ample gas exchange with the other. This study evaluated tumor ablations performed in an HOR equipped with cone beam CT and laser guidance.
MATERIALS AND METHODS: This retrospective study included patients who underwent lung tumor ablation under general anesthesia with an ETGA in an HOR between July 2020 and May 2023. Anesthesia considerations, perioperative management, and postoperative follow-ups were evaluated.
RESULTS: 65 patients (78 tumors) underwent ablation using two types of lung ventilation methods including a single-lumen tube with a blocker (SLT/BL) (n = 15) and double-lumen tube (DLT) (n = 50). Most patients experienced desaturation during the apnea phase of dynamic CT and needling. The average SpO2 value was significantly lower in the DLT group than in the SLT/BL group during the procedure (81.1% versus 88.7%, P = 0.033). Five, three, and two patients developed pneumothorax, subcutaneous emphysema, and pleural effusion, respectively.
CONCLUSION: Percutaneous ablation under general anesthesia with endotracheal intubation and lung separation performed in HORs was feasible and safe. The setup minimized complication risks and maintained a balance between patient safety and successful procedures.
NEW MATERIAL:A compound expressed by formula I [R is H or lower alkyl; X is CH=CH, CH2CH2 or CH2O; Y is 1-6C alkylene which may be replaced by lower alkyl or A-O-B (A and B are 1-3C alkylene which may be replaced by lower alkyl)] and salt thereof. EXAMPLE:Ethyl 4-(5H-dibenze[a,d]cycloheptene-5-ylidene)-1-piperidine propionate hydrochloride. USE:The compound expressed by formula I has antihistaminic and antiallergic action and is useful for treatment of bronchial asthma, allergic rhinitis, dermatosis, urticaria, etc. PREPARATION:A piperidine derivative expressed by formula II is reacted with a compound expressed by the formula Z-Y-COOR or the formula CH2= CH-COOR (Z is halogen) without using any solvent or in a solvent (e.g. N,N- dimethylformamide) in the presence (or absence) of a base (e.g. potassium carbonate) at 0-200 deg.C to provide the compound expressed by formula I.